Press Releases Pfizer Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:02 05/12/2025 GMT			After hours 00:56:29
26.03 ^USD	+1.28%		25.90	-0.50%

12-03	Mizuho's Katz sees 'fertile' conditions driving robust M&A market into 2026	RE
12-03	REUTERS NEXT -Mizuho's Katz sees 'fertile' conditions driving robust M&A market into 2026	RE

Press Releases

Pfizer : November Social Media Round-Up—Third-Quarter Earnings, Metsera Acquisition, and MoreUpdates & StatementsAlbert BourlaArtificial IntelligenceBusinessCancerHealth Equity • • •	12-03	PU
A Tale Told Through a Bird's Eyes: Jessica Mann's Uplift Reimagines How We See the Natural World	12-03	AQ
Pfizer : European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA™ (pembrolizumab) for Certain Patients with Muscle-Invasive Bladder CancerCorporatePartnerships	12-01	PU
Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance	12-01	BU
U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer	11-21	BU
Pfizer Completes Acquisition of Metsera	11-13	BU
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference	11-12	BU
Pfizer Pflash: A Spotlight on the PF’4404 (SSGJ-707 / PF-08634404) Clinical Development Strategy Transcript	11-12	PU
Pfizer Pflash: A Spotlight on the PF’4404 (SSGJ-707 / PF-08634404) Clinical Development Strategy Presentation	11-10	PU
Pfizer Responds to Delaware Chancery Court Ruling	11-05	BU
Pfizer : Quarterly Corporate Performance - Third Quarter 2025 Transcript	11-05	PU
Pfizer : Quarterly Corporate Performance - Third Quarter 2025 Press Release	11-04	PU
Pfizer : Quarterly Corporate Performance - Third Quarter 2025 Prepared Remarks	11-04	PU
Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer	11-04	AQ
Pfizer : Third Quarter 2025 Earnings Teleconference	11-04	PU
Pfizer: Q3 Earnings Snapshot	11-04	AQ
Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance	11-04	BU
Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk	11-03	BU
Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement	10-31	BU
Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition	10-31	BU
Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war	10-30	AQ
Pfizer Addresses Proposal for Metsera	10-30	BU
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology	10-27	PR
Pfizer : PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer	10-20	PU
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer	10-19	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Novo, Pfizer Boost Metsera Bids in Obesity Startup Battle

November 04, 2025 at 06:28 pm

Pfizer, Inc. under full-scale attack

October 08, 2024 at 11:16 am